CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

219293Orig1s000

NON-CLINICAL REVIEW(S)

MEMORANDUM

Date: September 26, 2024
To: File for NDA 219293
From: Daniela Torres, PhD
Pharmacology/Toxicology Reviewer
Division of Hematology Oncology Toxicology (DHOT)
Office of Oncologic Diseases (OOD)
Through: Brenda J. Gehrke, PhD
Pharmacology/Toxicology Supervisor
Subject: Nonclinical memorandum for NDA 219293
NDA: 219293
Applicant: Azurity Pharmaceuticals, Inc.
Product: DANZITEN (nilotinib tablets) 71 mg and 95 mg

On January 30, 2024, Azurity Pharmaceuticals submitted NDA 219293 for the marketing approval of DANZITEN (nilotinib tablets) 71 mg and 95 mg in accordance with Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. The application relies on the FDA's previous finding of safety for the listed drug (LD), TASIGNA (NDA 022068), as reflected in the drug's approved labeling. In a type B pre-IND meeting in 2019, the Agency agreed that no animal toxicology studies were necessary based on the proposed inactive ingredients, the intended controls on impurity levels, and the use of the tartrate salt form of nilotinib instead of the hydrochloride monohydrate form. In a pre-NDA meeting in 2022, the Agency agreed to the submission of only section 2.4 (nonclinical overview) and not section 2.6 since there were no new nonclinical studies. As previously discussed, no nonclinical studies were submitted with this NDA.

A comparison between the proposed nilotinib product and the LD is provided in the table below. Excipients not present in the LD are compendial and below the limits in the inactive ingredient database. Drug substance and drug product impurities are controlled according to ICH Q3A or ICH Q3B, respectively.

	DANZITEN	**TASIGNA**
Indication	Adult patients with CML	Adult and pediatric patients with CML
Active ingredient	Nilotinib tartrate	Nilotinib hydrochloride monohydrate
Route of administration	Oral	Oral
Dosage form	Tablet	Capsule
Strengths	71 mg, 95 mg	50 mg, 150 mg, 200 mg
Inactive ingredients	Hypromellose Acetate Succinate, NF Microcrystalline Cellulose, NF	Colloidal silicon dioxide Crospovidone Lactose monohydrate Magnesium stearate Poloxamer 188

	Croscarmellose Sodium, NF Colloidal Silicon Dioxide, NF Magnesium Stearate, NF Polyvinyl Alcohol, USP Titanium Dioxide, USP Polyethylene Glycol, USP Talc, USP Iron Oxide Red, NF Iron Oxide Yellow, NF	Gelatin Iron oxide (red) Iron oxide (yellow) Iron oxide (black) Titanium dioxide

USP= United States Pharmacopeia, NF= National Formulary

The label for the proposed nilotinib drug product was compared to the label for the LD, which was updated in 2021. The proposed nilotinib product is bioequivalent to the LD; therefore, the safety multiples in the LD's label apply to the proposed nilotinib drug product. One change was made in the Highlights, the text "Can cause fetal harm" was added to the Embryo-Fetal Toxicity Warnings and Precautions to be consistent with current labeling practice. No other changes were made to the label.

Recommendation: Recommended for approval. There are no Pharmacology/Toxicology concerns with the proposed nilotinib tablet drug product.

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DANIELA TORRES
09/26/2024 09:20:57 AM

BRENDA J GEHRKE
09/26/2024 12:37:27 PM